-
14 May 2025 23:16:46
- Source: Sharecast
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
Director Dealing
Cambridge, UK, 14 May 2025. Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces that Andrew Richards, Chair, has purchased 35,000 ordinary shares of £0.01 each in the capital of the Company ("Ordinary Shares") at a price of £0.4125 per Ordinary Share.
Following the transaction, the total beneficial interest of Andrew Richards is 286,611 Ordinary Shares, representing 0.76% of the total voting rights.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
www.arecor.com |
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
David Ellam, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Singer Capital Markets Advisory LLP (NOMAD and Broker) |
|
|
Phil Davies, Sam Butcher |
Tel: +44 (0) 20 7496 3000 |
|
|
|
|
ICR Healthcare |
|
|
Chris Gardner, David Daley, Lindsey Neville |
Tel: +44 (0) 20 3709 5700 Email: arecor@icrhealthcare.com |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Andrew Richards |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chair |
|
b) |
Initial notification/Amendment |
Initial notification |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name |
Arecor Therapeutics plc |
|
b) |
LEI |
98450093D1213A8DDD58 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument |
Ordinary Shares |
|
b) |
Identification Code |
GB00BMWLM973 |
|
c) |
Nature of the transaction |
Purchase of shares |
|
d) |
Price(s) and volume(s) |
£0.4125 and 35,000 Ordinary Shares |
|
e) |
Aggregated information - Aggregated volume - Aggregated price |
N/A |
|
f) |
Date of the transaction |
13 May 2025 |
|
g) |
Place of the transaction |
London Stock Exchange, AIM |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.